The aim of this study is to compare serum Sclerostin and Dickkopf-1 (Dkk-1) levels in patients with rheumatoid artrithis (RA) and healty controls to determine their clinical significance in patients with RA. Sixty with RA according to American Collage of Rhematology criteria and at least one year follow up, enrolled in this study and compared thırty healty controls. To evaluate disease activity score 28 (DAS28) was calculated. Physical function capasity (disability) was asssessed with Health Assesment Quastionnarie (HAQ) and Nottingham Health Profile (NHP). Erythrocyte Sedimentation Rate, C Reactive Protein, Rheumatoid Factor and anticyclic citrullinated peptide levels were determined by routine laboratory methods. Serum sclerostin and Dkk-1 levels of the patients with RA and healty controls were measured by ELISA. Radiographic assesment of hands joints was evaluated according to the modified Larsen score. Between patients with RA and healty controls, there was significant difference with respect to the age (respectively p=0.00) and significant difference with respect to gender (p=0.033). Serum sclerostin and dickkopf-1 levels were significantly higher (p=0.002, p=0.049) in patients with RA compared to healty controls. Serum sclerostin and dickkopf-1 levels were doesnt correlated with clinical and laboratory parameters of disease activity. There was no significant correlation between radiological scoring of joint damage and serum sclerostin and dickkopf-1levels (p 0.05). This study shows that Serum sclerostin and dickkopf-1 levels were increased in RA patients in comparison to control group but there was no significant correlation with the disease activity and joint damage. The sample of our study can be enlarged and further studies are required.
1. Dellhag B, Hosseini N, Bremell T, et al. Disturbed grip function in women with rheumatoid arthritis. J Rheumatol. 2001;28:2624-33.
2. Goronzy JJ, Weyand MC. Rheumatoid arthritis: Epidemiology, pathology and pathogenesis. Klippel JH (editor). Primer on the rheumatic diseases. Atlanta: Arthritis Foundation. 1997:155-61.
3. Ergin S. Romatoid artrit ve Sjögren sendromu. Beyazova M, Gökçe-Kutsal Y (editörler). Fiziksel Tıp ve Rehabilitasyon. Ankara: Öncü Basımevi, 2000;1549-76.
4. Fox DA. Etiology and pathogenesis of rheumatoid arthritis. Kopman WJ (editor). Arthritis and Allied Conditions. Philadelphia: Lippincott Williams and Wilkins. 2001:617-623
5. Deal C. Bone loss in rheumatoid arthritis: systemic, periarticular, and focal. Curr Rheumatol Rep. 2012;14:231-7.
6. Roux C. Osteoporosis in inflammatory joint diseases. Osteoporos In. 2011;22:421-33.
7. Sen M. Wnt signalling in rheumatoid arthritis. Rheumatology. 2005;44:708- 13.
8. Johnson ML, Kamel MA. The Wnt signaling pathway and bone metabolism. Curr Opin Rheumatol. 2007;19:376-82.
9. Fuchs HA, Pincus T. Reduced joint counts in controlled clinical trials in rheumatoid artrhritis. Arthritis Rheum. 1994;37:470-5.
10. Fries JF, Spitz P, Kraines RG, et al. Measurement of patients outcome in arthritis. Arthritis Rheum. 1980;23:137-45.
11. Andresen EM, Meyers AR. Health-related quality of life outcomes measures. Arch Phys Med Rehabil. 2000;81:30-45.
12. Gökçe-Kutsal Y, Osteoporoz tanısında görüntüleme yöntemleri ve histomorfometri, Ed: Gökçe-Kutsal Y, Osteoporoz, 2. Baskı, Ankara. Güneş Kitabevi. 2005:103-124.
13. Bağış S, Camdeviren H, Şahin G, ve ark. Osteoporoz risksorgulama formunun dexa ölçümü yapılacak hastaları ayırd etmede kullanımı. Osteoporoz Dünyasından. 2003;9:96-9.
14. Öncel S. Diğer periferik eklem osteoartritleri. Sarıdoğan M,ed. Tanıdan tedaviye osteoartrit. İstanbul: Nobel Tıp Kitabevi. 2007:163-73.
15. Larsen A. How to apply larsen score in evaluating radiographs of rheumatoid arthritis in long term studies. J Rheumatol 1995;22:1974-5.
16. Van der Heijde DM, van Riel PL, Nuver-Zwart IH, et al. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet. 1989;1:1036-8.
17. Van der Heijde DM, van Leeuwen MA, van Riel PL, et al. Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum. 1992;35:26-34.
18. Laan RF, Riel PL, Putte L. Bone mass in patients with rheumatoid arthritis. Ann Rheum Dis 1992;51:826-32.
19. Güler-Yüksel M, Bijsterbosch J, Goekoop-Ruiterman YP, et al. Bone mineral density in patients with recently diagnosed, acti- ve rheumatoid arthritis. Ann Rheum Dis. 2007;1508-12.
20. Rossini M, Viapiana O, Adami S, et al. In patients with rheumatoid arthritis, Dickkopf-1 serum levels are correlated with parathyroid hormone, bone erosions and bone mineral density. Clin Exp Rheumatol. 2015;33:77-83.
21. Pinzone JJ, Hall BM, Thudi NK, et al. The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood. 2009;113:517-25.
22. Marenzana M, Vugler A, Moore A, et al. Effect of sclerostin-neutralising antibody on periarticular and systemic bone in a murine model of rheumatoid arthritis: a microCT study. Arthritis Res Ther. 2013;15:125.
23. Daoussis D, Andonopoulos AP. The emerging role of Dickkopf-1 in bone biology: is it the main switch controlling bone and joint remodeling? Semin Arthritis Rheum. 2011;41:170-7.
24. Agnes S, Harjit PB, Antal-Szalmas, et al. Wnt pathway inhibitors in patients with psoriatic and rheumatoid arthritis treated with Anti-TNF Therapy. Arthritis & Rheumatism. 2012:64:144-9.
25. Wehmeyer C, Stratis A, Pap T, et al. The Role of the WNT inhibitor sclerostin in rheumatoid arthritis Bone/cartilage biology. Ann Rheum Dis. 2010;69:21.
26. Vis M, Havaardsholm EA, Haugeberg G, et al. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65:1495-9.
27. Guler-Yuksel M, Allaart CF, Watt I, et al. Treatment with TNF-a inhibitör infliximab might reduce hand osteoarthritis in patients with rheumatoid arthritis. Osteoarthritis Cartilage. 2010;18:1256-62.
28. Wang SY, Liu YY, Ye H, et al. Circulating Dickkopf-1 is correlated with bone erosion and inflammation in rheumatoid arthritis. J Rheumatol. 2011;38:821-7.
29. Mie Jin Lim, Seong Ryul Kwon, Kowoon Joo, et al. Early effects of tumor necrosis factor inhibition on bone homeostasis after soluble tumor necrosis factor receptor use. Korean J Intern Med. 2014;29:807–13.
30. Edwards CJ, Williams E. The role of interleukin-6 in rheumatoid arthritis associated osteoporosis. Osteoporos Int. 2010;21:1287-93.
31. Engvall IL, Svensson B, Tengstrand B, et al. Impact of low-dose prednisolone on bone synthesis and resorption in early rheumatoid arthritis: experiences from a two-year randomized study. Arthritis Res Ther. 2008;10:128.
32. Haugeberg G, Strand A, Kvien TK, et al. Reduced loss of hand bone density with prednisolone in early rheumatoid arthritis: results from a randomized placebo-controlled trial. Arch Intern Med. 2005;165:1293-7.
33. van Staa TP, Geusens P, Bijlsma JW, et al. Clinicalassessment of the longterm risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:3104-12.
34. Gifre L, Ruiz-Gaspà S, Monegal A,et al. Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover. Bone. 2013;57:272-6.
35. Seror R, Pavy S, Thierry S, et al. Abstract. Supplement Université Paris Sud, Le Kremlin Bicêtre, France, Arthritis & Rheumatism 2012:64.
36. Juarez M, Toellner DS, Yeo L, et al, Differential expression of DKK1 in synovial fibroblasts from patients with resolving and early rheumatoid arthritis. Pre-disease—What happens before diagnosis? Ann Rheum Dis. 2012;71:24.
37. Rossini M, Viapiana O, Zanotti R, et al. Dickkopf-1 and sclerostin serum levels in patients with systemic mastocytosis. Calcif Tissue Int. 2015;96:410-6.
38. Garnero P, Sornay-Rendu E, Munoz F, et al. Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study. Osteoporos Int. 2013;24:489-94.
39. Dawson-Hughes B, Harris SS, et al. Effect of supplemental vitamin D and calcium on serum sclerostin levels. Eur J Endocrinol. 2014;170:645-50.
40. Ahmed SF, Fouda N, Abbas AA. Serum dickkopf-1 level in post menopausal females: correlation with bone mineral density and serum biochemical markers. J Osteoporos. 2013;2013:460210.